About ACADIA Pharmaceuticals Inc.
https://www.acadia-pharm.comACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
CEO
Catherine E. Owen Adams
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 216
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
TD Cowen
Buy
UBS
Buy
Deutsche Bank
Buy
JMP Securities
Market Outperform
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:42.9M
Value:$1.15B
BLACKROCK, INC.
Shares:20.27M
Value:$544.42M
VANGUARD GROUP INC
Shares:15.18M
Value:$407.72M
Summary
Showing Top 3 of 426
About ACADIA Pharmaceuticals Inc.
https://www.acadia-pharm.comACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $278.63M ▲ | $221.23M ▲ | $71.78M ▲ | 25.76% ▲ | $0.43 ▲ | $47.55M ▲ |
| Q2-2025 | $264.57M ▲ | $211.46M ▲ | $26.67M ▲ | 10.08% ▲ | $0.16 ▲ | $35.31M ▲ |
| Q1-2025 | $244.32M ▼ | $204.63M ▲ | $18.99M ▼ | 7.77% ▼ | $0.11 ▼ | $22.24M ▲ |
| Q4-2024 | $259.6M ▲ | $84.3M ▼ | $143.74M ▲ | 55.37% ▲ | $0.87 ▲ | $12.2M ▼ |
| Q3-2024 | $250.4M | $199.9M | $32.77M | 13.09% | $0.2 | $31.64M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $847.02M ▲ | $1.33B ▲ | $413.5M ▲ | $917.27M ▲ |
| Q2-2025 | $762M ▲ | $1.23B ▲ | $403.17M ▲ | $822.38M ▲ |
| Q1-2025 | $681.58M ▼ | $1.13B ▼ | $367.13M ▼ | $765.24M ▲ |
| Q4-2024 | $755.99M ▲ | $1.19B ▲ | $454.96M ▲ | $732.79M ▲ |
| Q3-2024 | $565.33M | $976.87M | $399.69M | $577.18M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $71.78M ▲ | $74.29M ▲ | $-79.35M ▼ | $9.42M ▼ | $4.36M ▼ | $73.9M ▼ |
| Q2-2025 | $26.67M ▲ | $63.96M ▲ | $-43.29M ▲ | $15.96M ▲ | $36.64M ▲ | $162.5M ▲ |
| Q1-2025 | $18.99M ▼ | $20.32M ▼ | $-124.05M ▼ | $1.84M ▼ | $-101.89M ▼ | $-78.52M ▼ |
| Q4-2024 | $143.74M ▲ | $40.38M ▼ | $122.15M ▲ | $1.97M ▲ | $164.44M ▲ | $39.93M ▼ |
| Q3-2024 | $32.77M | $63.25M | $-82.46M | $268K | $-18.98M | $63.18M |
CEO
Catherine E. Owen Adams
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 216
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Needham
Buy
TD Cowen
Buy
UBS
Buy
Deutsche Bank
Buy
JMP Securities
Market Outperform
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:42.9M
Value:$1.15B
BLACKROCK, INC.
Shares:20.27M
Value:$544.42M
VANGUARD GROUP INC
Shares:15.18M
Value:$407.72M
Summary
Showing Top 3 of 426